Drug interactions between dofetilide and Inderide
| Results for the following 2 drugs: |
|---|
| dofetilide |
| Inderide (hydrochlorothiazide/propranolol) |
Interactions between your selected drugs
hydrochlorothiazide ↔ dofetilide
Applies to:Inderide (hydrochlorothiazide/propranolol) and dofetilide
CONTRAINDICATED: Coadministration with hydrochlorothiazide (HCTZ) may increase the plasma concentrations and pharmacodynamic effects of dofetilide. The mechanism of interaction has not been described. Concurrent administration of HCTZ (50 mg once a day) and dofetilide (500 mcg twice a day) for 5 days (following 2 days of diuretic use at half dose) has been shown to increase dofetilide peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 27%. However, the QTc increase over time and the maximum QTc increase values went up by 197% and 95%, respectively. In patients who received HCTZ-triamterene (50 mg-100 mg once a day) with dofetilide for 5 days, dofetilide Cmax was increased by 16% and AUC by 30%, while the QTc increase over time and maximum QTc increase values went up by 190% and 84%, respectively. The increased QT prolongation effects can be explained by a combination of the increase in dofetilide exposure and the HCTZ-induced reductions in serum potassium.
MANAGEMENT: Because QT interval prolongation may be associated with serious ventricular arrhythmias such as torsade de pointes tachycardia, use of dofetilide in combination with hydrochlorothiazide is considered contraindicated.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
